title: Genetic variation in the upstream region of ERG and prostate cancer.
abstract: OBJECTIVE
  A considerable fraction of prostate cancers harbor a gene fusion between the androgen-regulated TMPRSS2 and ERG, one of the most frequently over-expressed proto-oncogenes in prostate cancer. Here, we investigated if inherited genetic variation upstream of ERG alters prostate cancer risk and survival.
  
  
  METHODS
  We genotyped 21 haplotype tagging SNPs (htSNPs) covering 123 kb of 5'UTR DNA including exon 3 of ERG in 2,760 incident prostate cancer cases and 1,647 controls from a population-based Swedish case-control study (CAPS). Individual SNPs and haplotypes were tested for association with prostate cancer risk and survival.
  
  
  RESULTS
  One haplotype-'CTCGTATG' located 100 kb upstream of ERG-was associated with lethal prostate cancer (HR, 1.36; 95% CI, 1.2-1.9, p = 0.006). Carriers of the variant 'T' allele of rs2836626 were diagnosed with higher TNM-stage (p = 0.009) and had an increased risk of prostate cancer-specific death (HR = 1.3; 95% CI, 1.1-1.7, p = 0.009). However, this association did not remain statistically significant after adjusting for multiple testing. We found overall no association between ERG variation and prostate cancer risk.
  
  
  CONCLUSIONS
  Genetic variation upstream of ERG may alter prostate cancer stage and ultimately prostate cancer-specific death but it is unlikely that it plays a role in prostate cancer development.
authors.affiliation: Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. slindstr@hsph.harvard.edu
authors.forename: Sara
authors.initials: S
authors.lastname: Lindström
authors.forename: Hans-Olov
authors.initials: HO
authors.lastname: Adami
authors.forename: Katarina
authors.initials: K
authors.lastname: Bälter
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Xu
authors.forename: S Lilly
authors.initials: SL
authors.lastname: Zheng
authors.forename: Jielin
authors.initials: J
authors.lastname: Sun
authors.forename: Pär
authors.initials: P
authors.lastname: Stattin
authors.forename: Henrik
authors.initials: H
authors.lastname: Grönberg
authors.forename: Fredrik
authors.initials: F
authors.lastname: Wiklund
mesh_terms: D000368:Aged; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality; D011519:Proto-Oncogenes / Q000235:genetics; D012307:Risk Factors; D012697:Serine Endopeptidases / Q000235:genetics; D016019:Survival Analysis; D015534:Trans-Activators / Q000235:genetics*; D000071230:Transcriptional Regulator ERG
chemical_list: C072312:ERG protein, human; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D012697:Serine Endopeptidases; C421305:TMPRSS2 protein, human